Coherus BioSciences (NASDAQ:CHRS) Given New $6.00 Price Target at Robert W. Baird

Coherus BioSciences (NASDAQ:CHRS) had its price target boosted by Robert W. Baird from $4.00 to $6.00 in a research note published on Thursday,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

CHRS has been the subject of a number of other research reports. UBS Group cut Coherus BioSciences from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $4.00 to $1.50 in a research report on Friday, August 16th. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Coherus BioSciences in a report on Wednesday. Finally, StockNews.com lowered Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Coherus BioSciences currently has an average rating of “Moderate Buy” and a consensus price target of $5.38.

Coherus BioSciences Stock Performance

Coherus BioSciences stock opened at $1.51 on Thursday. The stock has a market cap of $173.97 million, a PE ratio of -18.88 and a beta of 0.86. Coherus BioSciences has a one year low of $0.66 and a one year high of $3.70. The stock has a fifty day moving average of $0.97 and a 200 day moving average of $1.32.

Hedge Funds Weigh In On Coherus BioSciences

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in shares of Coherus BioSciences by 7.7% in the third quarter. Geode Capital Management LLC now owns 2,565,145 shares of the biotechnology company’s stock worth $2,668,000 after acquiring an additional 182,914 shares during the period. XTX Topco Ltd lifted its position in shares of Coherus BioSciences by 74.5% in the third quarter. XTX Topco Ltd now owns 473,517 shares of the biotechnology company’s stock worth $492,000 after buying an additional 202,084 shares in the last quarter. Systematic Financial Management LP purchased a new stake in shares of Coherus BioSciences in the third quarter worth about $28,000. FMR LLC lifted its position in shares of Coherus BioSciences by 21.1% in the third quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock worth $234,000 after buying an additional 39,204 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Coherus BioSciences by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 964,327 shares of the biotechnology company’s stock worth $1,003,000 after buying an additional 116,217 shares in the last quarter. Institutional investors own 72.82% of the company’s stock.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.